JP2019201643A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019201643A5 JP2019201643A5 JP2019111990A JP2019111990A JP2019201643A5 JP 2019201643 A5 JP2019201643 A5 JP 2019201643A5 JP 2019111990 A JP2019111990 A JP 2019111990A JP 2019111990 A JP2019111990 A JP 2019111990A JP 2019201643 A5 JP2019201643 A5 JP 2019201643A5
- Authority
- JP
- Japan
- Prior art keywords
- isolated antibody
- functional fragment
- antibody
- domain
- collection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000012634 fragment Substances 0.000 claims 13
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 239000013598 vector Substances 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004602 germ cell Anatomy 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021169020A JP2022028659A (ja) | 2013-06-26 | 2021-10-14 | 新規抗体フレームワーク |
| JP2023199881A JP2024026176A (ja) | 2013-06-26 | 2023-11-27 | 新規抗体フレームワーク |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13003264.2 | 2013-06-26 | ||
| EP13003264 | 2013-06-26 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016522319A Division JP6708544B2 (ja) | 2013-06-26 | 2014-06-26 | 新規抗体フレームワーク |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021169020A Division JP2022028659A (ja) | 2013-06-26 | 2021-10-14 | 新規抗体フレームワーク |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019201643A JP2019201643A (ja) | 2019-11-28 |
| JP2019201643A5 true JP2019201643A5 (enExample) | 2020-01-16 |
Family
ID=48699516
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016522319A Active JP6708544B2 (ja) | 2013-06-26 | 2014-06-26 | 新規抗体フレームワーク |
| JP2019111990A Withdrawn JP2019201643A (ja) | 2013-06-26 | 2019-06-17 | 新規抗体フレームワーク |
| JP2021169020A Pending JP2022028659A (ja) | 2013-06-26 | 2021-10-14 | 新規抗体フレームワーク |
| JP2023199881A Pending JP2024026176A (ja) | 2013-06-26 | 2023-11-27 | 新規抗体フレームワーク |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016522319A Active JP6708544B2 (ja) | 2013-06-26 | 2014-06-26 | 新規抗体フレームワーク |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021169020A Pending JP2022028659A (ja) | 2013-06-26 | 2021-10-14 | 新規抗体フレームワーク |
| JP2023199881A Pending JP2024026176A (ja) | 2013-06-26 | 2023-11-27 | 新規抗体フレームワーク |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10174102B2 (enExample) |
| EP (1) | EP3013864A1 (enExample) |
| JP (4) | JP6708544B2 (enExample) |
| KR (4) | KR20220029763A (enExample) |
| CN (2) | CN105579472B (enExample) |
| AU (2) | AU2014301629B2 (enExample) |
| CA (1) | CA2914829A1 (enExample) |
| HK (1) | HK1218549A1 (enExample) |
| IL (3) | IL243311B (enExample) |
| NZ (1) | NZ714320A (enExample) |
| SG (2) | SG10201811017QA (enExample) |
| WO (1) | WO2014206561A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL243311B (en) | 2013-06-26 | 2022-07-01 | Numab Therapeutics AG | New frameworks for antibodies |
| IL293435B1 (en) | 2015-06-15 | 2026-04-01 | Numab Therapeutics AG | Heterodimeric multispecific antibody format |
| US20190048085A1 (en) | 2016-02-25 | 2019-02-14 | Cell Medica Switzerland Ag | Modified cells for immunotherapy |
| IL261098B2 (en) | 2016-03-17 | 2024-09-01 | Numab Therapeutics AG | Antibodies against TNF-ALPHA and their functional fragments |
| DK3219726T3 (da) | 2016-03-17 | 2020-12-07 | Tillotts Pharma Ag | Anti-TNF-alfa-antistoffer og funktionelle fragmenter deraf |
| EP3430041B1 (en) | 2016-03-17 | 2023-05-24 | Numab Innovation AG | Anti-tnfalpha-antibodies and functional fragments thereof |
| US10774140B2 (en) | 2016-03-17 | 2020-09-15 | Numab Therapeutics AG | Anti-TNFα-antibodies and functional fragments thereof |
| PL3219727T3 (pl) | 2016-03-17 | 2021-05-17 | Tillotts Pharma Ag | Przeciwciała anty-TNF alfa i ich funkcjonalne fragmenty |
| GB201621591D0 (en) * | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Antibody molecules and method |
| EP3634998B8 (en) | 2017-06-05 | 2025-04-09 | Numab Therapeutics AG | Anti-cd3 epsilon antibodies |
| SG11201911527QA (en) | 2017-06-05 | 2020-01-30 | Numab Therapeutics AG | Hetero-dimeric multi-specific antibody format targeting at least cd3 and hsa |
| MA49249A (fr) | 2017-06-05 | 2021-04-14 | Numab Therapeutics AG | Nouveaux anticorps anti-hsa |
| WO2018224441A1 (en) | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-cd3 antibodies |
| WO2018224439A1 (en) | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-hsa antibodies |
| US20200157224A1 (en) * | 2017-06-25 | 2020-05-21 | Systimmune, Inc. | Multi-specific antibodies and methods of making and using thereof |
| KR102763369B1 (ko) | 2017-06-25 | 2025-02-05 | 시스트이뮨, 인코포레이티드 | 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도 |
| EP3459968A1 (en) * | 2017-09-20 | 2019-03-27 | Numab Innovation AG | Novel stable antibody variable domain framework combinations |
| EP4591879A3 (en) | 2019-01-31 | 2025-10-22 | Numab Therapeutics AG | Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof |
| EP3689907A1 (en) | 2019-01-31 | 2020-08-05 | Numab Therapeutics AG | Antibodies targeting il-17a and methods of use thereof |
| CA3203552A1 (en) * | 2020-12-30 | 2022-07-07 | Ascendo Biotechnology, Inc. | Monoclonal antibody against human mac-1 and uses thereof |
| WO2022171771A1 (en) | 2021-02-12 | 2022-08-18 | Boehringer Ingelheim International Gmbh | Complement c3 antigen binding proteins |
| EP4305190A4 (en) | 2021-03-11 | 2025-03-26 | Iggenix, Inc. | METHODS AND SYSTEMS FOR PREDICTING AN ALLERGIC REACTION |
| CR20240265A (es) | 2021-12-22 | 2024-10-16 | Boehringer Ingelheim Int | Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares |
| JP2025542567A (ja) * | 2022-11-04 | 2025-12-26 | ミンク セラピューティクス，インコーポレイティッド | Ｂ細胞成熟抗原（ｂｃｍａ）キメラ抗原受容体インバリアントナチュラルキラーｔ細胞及びその用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| AU2003259718A1 (en) | 2003-08-07 | 2005-03-07 | Epitomics, Inc. | Methods for humanizing rabbit monoclonal antibodies |
| WO2008004834A1 (en) | 2006-07-06 | 2008-01-10 | Isu Abxis Co., Ltd | Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor |
| FR2910896B1 (fr) * | 2006-12-29 | 2012-11-16 | Lab Francais Du Fractionnement | Anticorps monoclonal dirige contre le recepteur humain des ldl |
| KR20170036814A (ko) | 2007-05-21 | 2017-04-03 | 앨더바이오 홀딩스 엘엘씨 | 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체 |
| BRPI0813645A2 (pt) | 2007-06-25 | 2014-12-30 | Esbatech Alcon Biomed Res Unit | Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas |
| PL2307458T3 (pl) * | 2008-06-25 | 2018-08-31 | Esbatech, An Alcon Biomedical Research Unit Llc | Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała |
| KR102050040B1 (ko) * | 2008-06-25 | 2019-11-28 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | ＴＮＦα를 저해하는 안정한 가용성 항체 |
| BRPI0914251B1 (pt) * | 2008-06-25 | 2022-07-19 | Novartis Ag | Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição |
| US8193235B2 (en) | 2009-06-12 | 2012-06-05 | University Of Kansas | Compositions and methods for establishing and maintaining stem cells in an undifferentiated state |
| BR112012027917A2 (pt) * | 2010-04-30 | 2017-11-28 | Alexion Pharma Inc | anticorpos que apresentam reduzida imunogenicidade em um indivíduo humano |
| EP2726504A1 (en) * | 2011-05-27 | 2014-05-07 | Dutalys | Antibodies with improved folding stability |
| IL243311B (en) | 2013-06-26 | 2022-07-01 | Numab Therapeutics AG | New frameworks for antibodies |
| EP3459968A1 (en) | 2017-09-20 | 2019-03-27 | Numab Innovation AG | Novel stable antibody variable domain framework combinations |
-
2014
- 2014-06-26 IL IL243311A patent/IL243311B/en unknown
- 2014-06-26 NZ NZ714320A patent/NZ714320A/en unknown
- 2014-06-26 CA CA2914829A patent/CA2914829A1/en active Pending
- 2014-06-26 KR KR1020227006072A patent/KR20220029763A/ko not_active Ceased
- 2014-06-26 JP JP2016522319A patent/JP6708544B2/ja active Active
- 2014-06-26 US US14/900,550 patent/US10174102B2/en active Active
- 2014-06-26 KR KR1020167001339A patent/KR102286053B1/ko active Active
- 2014-06-26 IL IL293477A patent/IL293477B2/en unknown
- 2014-06-26 SG SG10201811017QA patent/SG10201811017QA/en unknown
- 2014-06-26 KR KR1020217024096A patent/KR20210097829A/ko not_active Ceased
- 2014-06-26 CN CN201480036689.1A patent/CN105579472B/zh active Active
- 2014-06-26 KR KR1020237043185A patent/KR20240000622A/ko active Pending
- 2014-06-26 SG SG11201509899PA patent/SG11201509899PA/en unknown
- 2014-06-26 HK HK16106054.2A patent/HK1218549A1/zh unknown
- 2014-06-26 CN CN202111136784.7A patent/CN113943366B/zh active Active
- 2014-06-26 EP EP14737144.7A patent/EP3013864A1/en active Pending
- 2014-06-26 AU AU2014301629A patent/AU2014301629B2/en active Active
- 2014-06-26 IL IL313351A patent/IL313351B1/en unknown
- 2014-06-26 WO PCT/EP2014/001730 patent/WO2014206561A1/en not_active Ceased
-
2018
- 2018-10-10 US US16/156,036 patent/US11427628B2/en active Active
-
2019
- 2019-06-17 JP JP2019111990A patent/JP2019201643A/ja not_active Withdrawn
-
2020
- 2020-04-27 AU AU2020202770A patent/AU2020202770B2/en active Active
-
2021
- 2021-10-14 JP JP2021169020A patent/JP2022028659A/ja active Pending
-
2022
- 2022-08-29 US US17/822,959 patent/US20230212265A1/en active Pending
-
2023
- 2023-11-27 JP JP2023199881A patent/JP2024026176A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019201643A5 (enExample) | ||
| HRP20251150T1 (hr) | Anti-her2 protutijela i postupci uporabe | |
| JP2021508469A5 (enExample) | ||
| JP2019501883A5 (enExample) | ||
| JP2020525032A5 (enExample) | ||
| JP2018522541A5 (enExample) | ||
| HRP20231134T1 (hr) | Humanizirana i afinitetno zrela protutijela na fcrh5 i postupci za uporabu | |
| HRP20200583T1 (hr) | Protutijela koja neutraliziraju gp120 i njihova upotreba | |
| JP2019054802A5 (enExample) | ||
| JP2018035138A5 (enExample) | ||
| JP2020504101A5 (enExample) | ||
| JP2020535799A5 (enExample) | ||
| JP2018521638A5 (enExample) | ||
| JP2021500853A5 (enExample) | ||
| JP2018506961A5 (enExample) | ||
| JP2021532058A5 (enExample) | ||
| JP2017514461A5 (enExample) | ||
| FI3322727T3 (fi) | Humanisoituja tai kimeerisiä CD3-vasta-aineita | |
| JP2015163068A5 (enExample) | ||
| JP2020514277A5 (enExample) | ||
| JP2018526981A5 (enExample) | ||
| JP2020519308A5 (enExample) | ||
| JP2016533763A5 (ja) | ヒトｐｄ−１に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物 | |
| JP2013198490A5 (enExample) | ||
| RU2017134495A (ru) | Антитела к альфа-рецептору собачьего интерлейкина-4 |